| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| Cathepsin B | Human Cathepsin B / CTSB (L26V) Protein, Tag Free (Pro-form, MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $367.00 50ug | |||
| Cathepsin B | Human Cathepsin B / CTSB Protein, His Tag (Pro-form, Mass Spec & MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $400.00 50ug | |||
| Cathepsin B | Human Cathepsin B / CTSB (18-339) Protein, His Tag (Pro-form, MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $367.00 50ug | |||
| Cathepsin B | Mouse Cathepsin B / CTSB Protein, His Tag (Pro-form, MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $350.00 50ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Osugacestat | AL-101(BMS); BMS-906024; BM-0018 | Phase 2 Clinical | Bristol-Myers Squibb Company, Glaxosmithkline Plc | Carcinoma, Adenoid Cystic; Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Triple Negative Breast Neoplasms | Details |
| cysteine protease inhibitor (Boehringer Ingelheim) | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Respiratory Tract Diseases | Details |
